NASDAQ : MSLE
Satellos Bioscience Inc. — Key statistics
Healthcare · Biotechnology · Canada
Last price 6.815 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 145.77M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 137.42M |
| Enterprise Value | 74.57M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 15, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 21.22M |
| Shares Outstanding | 21.22M |
| Shares Change (YoY) | +46.32% |
| Shares Change (QoQ) | +13.00% |
| Owned by Insiders (%) | 6.94% |
| Owned by Institutions (%) | 41.60% |
| Float | 18.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.29 |
| P/TBV Ratio | 2.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 11.22 |
| Quick Ratio | 10.68 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -70.45% |
| Return on Assets (ROA) | -41.89% |
| Return on Invested Capital (ROIC) | -45.57% |
| Return on Capital Employed (ROCE) | -59.79% |
| Weighted Average Cost of Capital (WACC) | 10.55% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.65M |
| Employee Count | 21 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 154,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.15 |
| 52-Week Price Change | -1.52% |
| 50-Day Moving Average | 8.21 |
| 200-Day Moving Average | 8.48 |
| Relative Strength Index (RSI) | 36.83 |
| Average Volume (20 Days) | 46,395 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 97,288 |
| Short Previous Month | 105,687 |
| Short % of Shares Out | 0.46% |
| Short % of Float | 0.54% |
| Short Ratio (days to cover) | 1.48 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -9.48M |
| Operating Income | -35.82M |
| Pretax Income | -34.46M |
| Net Income | -34.61M |
| EBITDA | -35.82M |
| EBIT | -35.82M |
| Earnings Per Share (EPS) | -$2.02 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 61.84M |
| Total Debt | n/a |
| Net Cash | 61.84M |
| Net Cash Per Share | $2.91 |
| Equity (Book Value) | 59.91M |
| Book Value Per Share | 2.87 |
| Working Capital | 59.90M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -29.00M |
| Capital Expenditures | -7,000 |
| Depreciation & Amortization | 5,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -29.01M |
| FCF Per Share | -$1.37 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -46.32% |
| Shareholder Yield | -46.32% |
| Earnings Yield | -31.56% |
| FCF Yield | -21.11% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $24.17 |
| Price Target Difference | 277.66% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 30, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |